In re Lipitor Antitrust Litigation
Feb, 2025
In re Lipitor Antitrust Litigation (D.N.J.)
This is a federal antitrust action seeking to recover overcharges caused by alleged unlawful tactics used to delay entry of generic versions of Lipitor (atorvastatin calcium) into the United States market. Lipitor belongs to a class of drugs called statins, which are prescribed to lower LDL (bad) cholesterol and reduce the risk of stroke and coronary heart disease. NastLaw represents a class of persons and entities that purchased brand or generic Lipitor directly from one of the named Defendants. The Court has preliminarily approved a settlement agreement with Pfizer for $93 million.